Literature DB >> 1313797

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

J Eng1, W A Kleinman, L Singh, G Singh, J P Raufman.   

Abstract

The recent identification in Heloderma horridum venom of exendin-3, a new member of the glucagon superfamily that acts as a pancreatic secretagogue, prompted a search for a similar peptide in Heloderma suspectum venom. An amino acid sequencing assay for peptides containing an amino-terminal histidine residue (His1) was used to isolate a 39-amino acid peptide, exendin-4, from H. suspectum venom. Exendin-4 differs from exendin-3 by two amino acid substitutions, Gly2-Glu3 in place of Ser2-Asp3, but is otherwise identical. The structural differences make exendin-4 distinct from exendin-3 in its bioactivity. In dispersed acini from guinea pig pancreas, natural and synthetic exendin-4 stimulate a monophasic increase in cAMP beginning at 100 pM that plateaus at 10 nM. The exendin-4-induced increase in cAMP is inhibited progressively by increasing concentrations of the exendin receptor antagonist, exendin-(9-39) amide. Unlike exendin-3, exendin-4 does not stimulate a second rise in acinar cAMP at concentrations greater than 100 nM, does not stimulate amylase release, and does not inhibit the binding of radiolabeled vasoactive intestinal peptide to acini. This indicates that in dispersed pancreatic acini, exendin-4 interacts only with the recently described exendin receptor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313797

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  225 in total

Review 1.  Bowels control brain: gut hormones and obesity.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Nat Rev Endocrinol       Date:  2010-06-29       Impact factor: 43.330

Review 2.  The structure and function of the glucagon-like peptide-1 receptor and its ligands.

Authors:  Dan Donnelly
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Extending residence time and stability of peptides by protected graft copolymer (PGC) excipient: GLP-1 example.

Authors:  Gerardo M Castillo; Sandra Reichstetter; Elijah M Bolotin
Journal:  Pharm Res       Date:  2011-08-04       Impact factor: 4.200

4.  The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.

Authors:  R J Mann; N E Nasr; J K Sinfield; E Paci; D Donnelly
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

5.  Absence of exendin-4 effects on postprandial glucose and lipids in the Gila monster, Heloderma suspectum.

Authors:  Carolyn M Christel; Dale F Denardo
Journal:  J Comp Physiol B       Date:  2006-09-14       Impact factor: 2.200

6.  Fluorescent exendin-4 derivatives for pancreatic β-cell analysis.

Authors:  Susan M Clardy; Edmund J Keliher; James F Mohan; Matt Sebas; Christophe Benoist; Diane Mathis; Ralph Weissleder
Journal:  Bioconjug Chem       Date:  2013-12-20       Impact factor: 4.774

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.

Authors:  Nigel H Greig; David Tweedie; Lital Rachmany; Yazhou Li; Vardit Rubovitch; Shaul Schreiber; Yung-Hsiao Chiang; Barry J Hoffer; Jonathan Miller; Debomoy K Lahiri; Kumar Sambamurti; Robert E Becker; Chaim G Pick
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

9.  Interspecies modeling and prediction of human exenatide pharmacokinetics.

Authors:  Ting Chen; Donald E Mager; Leonid Kagan
Journal:  Pharm Res       Date:  2012-11-15       Impact factor: 4.200

Review 10.  Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.

Authors:  Baptist Gallwitz
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.